A Bayesian Re-Analysis of the GALFLU Trial of high dose versus standard dose influenza vaccine against hospitalisation outcomes
Clicks: 4
ID: 323535
2026
Article Quality & Performance Metrics
Overall Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
0.0
/100
0 views
0 readers
AI Quality Assessment
Not analyzed
Abstract
Abstract The GALFLU trial showed a lower incidence of hospitalisation among adults aged 65-79 years randomised to high-dose inactivated influenza vaccine (HD-IIV) compared with standard-dose inactivated influenza vaccine (SD-IIV). This Bayesian re-analysis estimated an >80% probability of benefit (rVE >10%) against influenza-or-pneumonia-related hospitalisation, supporting the benefit of HD-IIV over SD-IIV.
| Reference Key |
openalex_W7172326579
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Jacobo Pardo-Seco, Carmen Rodríguez-Tenreiro-Sánchez, Iago Giné-Vázquez, Narmeen Mallah, Susana Mirás-Carballal, Marta Piñeiro-Sotelo, Martín Cribeiro González, M. Pájaro, Juan-Manuel González-Pérez, Irene Rivero‐Calle, Xabier Bello, Josefina L Razzini, Antonio Salas, Rebecca C. Harris, Matthew M. Loiacono, Robertus van Aalst, J. Manel Farré Avellà, Marine Dufournet, Niklas Dyrby Johansen, Daniel Modin, Tor Biering-Sørensen, Carmen Durán‐Parrondo, Federico Martinón‐Torres |
| Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |
| Year | 2026 |
| DOI |
10.1093/cid/ciag466
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.